Welcome to our dedicated page for TACTILE SYSTEMS TECHNOLOGY SEC filings (Ticker: TCMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tactile Systems Technology, Inc. filings document a Nasdaq-listed medical technology issuer with common stock registered under the ticker TCMD. Recent Form 8-K reports disclose quarterly and annual operating results, financial condition updates, acquisition-related Regulation FD materials, FDA and product-related business highlights, share repurchase authorization activity and other corporate events.
The company's proxy and governance filings cover board composition, director elections, committee assignments, executive compensation, shareholder voting matters and amendments to its certificate of incorporation. Its SEC disclosures also identify Delaware incorporation, Nasdaq listing status, capital actions and governance provisions relevant to its public-company structure.
Birkemeyer Elaine M. reported acquisition or exercise transactions in this Form 4 filing.
Tactile Systems Technology chief financial officer Elaine M. Birkemeyer received a grant of 23,008 shares of common stock in the form of restricted stock units at a stated price of $0.0000 per share. Following this award, her directly held common stock position reported in this filing is 122,119 shares.
The RSUs vest over three years, with one-third of the units vesting on each of the first three anniversaries of the grant date, meaning the compensation is spread over time and depends on continued service.
Kristie Burns submitted a Form 144 notice to sell common stock. The filing lists 4,439 shares tied to restricted stock vesting on 02/20/2026 and shows $125,610.38 alongside a Fidelity brokerage record. It also reports 5,139 shares sold on 01/02/2026 for $148,260.15.
Tactile Systems Technology, Inc. reports full-year 2025 results and provides a detailed overview of its medical technology business focused on at-home treatment of chronic diseases. The company generated $329.5 million in revenue and $19.1 million in net income for 2025, with revenue growing 12% year over year.
Lymphedema products, including Flexitouch Plus, Entre Plus and Nimbl, produced $278.4 million or 84% of 2025 revenue, while the AffloVest airway clearance product line contributed $51.1 million or 16%. Tactile highlights broad U.S. reimbursement coverage, in‑network payer contracts covering about 278 million lives, and a largely direct-to-patient model for lymphedema alongside a DME distribution model for AffloVest.
The filing emphasizes extensive clinical evidence supporting Flexitouch, Nimbl and AffloVest, ongoing R&D investment of $8.5 million in 2025, and a sizable commercial organization with 166 account managers and 185 specialists as of December 31, 2025. Management also outlines significant market opportunities in lymphedema, chronic venous insufficiency and bronchiectasis, while detailing the regulatory, reimbursement and fraud-and-abuse frameworks governing its operations.
Tactile Systems Technology reported strong fourth quarter and full-year 2025 results and announced a strategic acquisition. Fourth quarter revenue rose 21% to $103.6 million, with operating income up to $18.8 million and net income of $10.6 million, or $0.46 per diluted share. Full-year 2025 revenue grew 12% to $329.5 million, driven by 7% growth in lymphedema products and 52% growth in airway clearance products. Net income increased to $19.1 million and Adjusted EBITDA rose to $44.8 million, reflecting improved profitability.
The company ended 2025 with $83.4 million in cash and no debt after repaying $26.3 million of term loan borrowings and repurchasing $26.5 million of stock. For 2026, it guides revenue to $357–$365 million and Adjusted EBITDA to $49–$51 million, implying continued growth. Separately, Tactile Medical acquired LymphaTech Inc. for an upfront cash payment of $6.8 million plus potential milestone-based consideration, adding a 3D digital measurement platform to deepen its lymphedema solutions portfolio.
Cadian Capital filed an amended Schedule 13G/A showing passive ownership in Tactile Systems Technology, Inc. common stock. As of December 31, 2025, Cadian Capital Management, its general partner, and Eric Bannasch were deemed to beneficially own 1,084,094 shares, or about 4.9% of the outstanding common stock.
All shares are held by advisory clients of Cadian Capital Management, over which the adviser has shared voting and investment power. The filing certifies the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
Paradigm Capital Management, Inc. filed an amended Schedule 13G reporting a passive ownership stake in Tactile Systems Technology, Inc. common stock. As of December 31, 2025, Paradigm beneficially owned 736,599 shares, representing 3.29% of the company’s common stock, with sole voting and dispositive power.
The firm states the shares were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing control of Tactile Systems Technology.
Morgan Stanley and Morgan Stanley Capital Services LLC have disclosed significant passive stakes in Tactile Systems Technology Inc. common stock. As of 12/31/2025, Morgan Stanley reports beneficial ownership of 1,293,289 shares, representing 5.8% of the class, with all voting and dispositive power shared.
Morgan Stanley Capital Services LLC reports beneficial ownership of 1,154,700 shares, or 5.2% of the class, also with shared voting and dispositive power. The firms certify the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of Tactile Systems Technology.
Dimensional Fund Advisors LP has filed an amended Schedule 13G reporting beneficial ownership of Tactile Systems Technology Inc common stock. Dimensional is reported as having beneficial ownership of 1,095,235 shares, representing 4.9% of the outstanding common stock as of the event date of 12/31/2025. It has sole voting power over 1,069,882 shares and sole dispositive power over 1,095,235 shares.
The shares are owned by various funds and accounts that Dimensional advises or manages, and Dimensional disclaims beneficial ownership beyond what is required for Section 13(d) reporting. The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Tactile Systems Technology Inc.